Zoekresultaten - You searched for Clinical Trials

434 results

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Read more

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

Read more

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Read more

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

Read more

Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment

Read more

Seminar: How Real World Data will change your clinical development to the better

Read more

Seminar: How Real World Data will change your clinical development to the better

Read more

Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

Read more

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

argenx reports third quarter 2017 financial results and provides business update

Read more

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Read more

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Read more

argenx reports fourth quarter business update and full year 2017 financial results

Read more

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

Read more

argenx reports first quarter 2018 financial results and provides business update

Read more

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

Read more

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

Read more

Acacia Pharma announces its intention to launch an initial global offering and to list its shares on Euronext Brussels

Read more

Gilead and Galapagos announce results with filgotinib in the phase 2 equator study in psoriatic arthritis and progression into phase 3 for the selection study in ulcerative colitis

Read more

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Read more

argenx reports first quarter 2017 financial results and provides business update

Read more

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Read more

eTheRNA immunotherapies advances In-Vivo mRNA Cancer Immunotherapy into first Oncology Clinical Studies

Read more

Celyad announces initiation of the SHRINK trial

Read more

Dosing of First Patient with investigational agent OMO-1

Read more

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

Read more

Bone Therapeutics Business Update for Third Quarter 2017

Read more

Celyad Announces Third Quarter 2017 Business Update

Read more

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

Read more

Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

Read more

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

Read more

Patient centricity in Clinical Research

Read more

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

Read more

iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor

Read more

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla(TM) platform

Read more

Convert Pharmaceuticals secures EUR 13,6 million to develop anti-cancer drugs

Read more

Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement

Read more

Biocartis Selected for Oral Presentation at Cancer Research Meeting

Read more

eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Read more

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

Read more

Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April

Read more

argenx appoints Keith Woods as Chief Operating Officer

Read more

Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates

Read more

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma

Read more

Galapagos announces ISABELA Phase 3 program in IPF

Read more

ProDigest: PROMISE

Read more

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149

Read more

Webinar: A comprehensible jumpstart towards gcp computer system validation anno 2018

Read more

argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

Read more

Kiadis Pharma announces Annual Results for the year ended December 31, 2016

Read more

Argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Read more

Bootcamp in Entrepreneurial Innovation in Orphan Diseases

Read more

TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week

Read more

Galapagos NV: Seven abstracts on filgotinib accepted by EULAR 2017

Read more

Celyad Announces First Quarter 2017 Business Update

Read more

TiGenix Launches Global Phase III Trial for Cx601

Read more

Kiadis Pharma raises €5 million in private placement with institutional investors

Read more

argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas

Read more

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

Read more

argenx reports second quarter business update and half-year 2017 financial results

Read more

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Read more

R-Biopharm AG & UgenTec partner to develop software for automated PCR analysis

Read more

ONTOFORCE and akcelis collaborate to create and share infographics

Read more

Camel-IDS appoints Ruth Devenyns as Chief Executive Officer

Read more

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Read more

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Read more

Mithra Provides Update on Estelle® and Donesta® Studies

Read more

The Adecco Group Announces the Acquisition of CMAST

Read more

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Read more

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Read more

Scientists discover how treating eczema could also alleviate asthma

Read more

Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration

Read more

Ablynx announces 2017 full year results

Read more

Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease

Read more

VIB Plant-derived volatiles may serve as future antifungals

Read more

UgenTec: announcing our $ 9.3 million Series A funding

Read more

Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders' Meeting

Read more

UgenTec Announces partnership with Serosep Ltd.

Read more

MDxHealth Announces Positive Clinical Updates for ConfirmMDx

Read more

Mithra launches capital increase by means of a private placement via an accelerated bookbuild offering

Read more

Mithra successfully raises eur 77.5 million

Read more

Mithra Announces Presentation of Donesta® Results at the International Menopause Society’s 16th World Congress

Read more

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Read more

argenx receives first preclinical milestone payment in AbbVie collaboration

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

argenx files registration statement for a proposed public offering in the United States

Read more

argenx announces results of Annual General Meeting 2017

Read more

Galapagos reports first quarter 2017 results

Read more

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Read more

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Read more

argenx announces launch of proposed initial public offering in the United States

Read more

Bone Therapeutics Business Update for First Quarter 2017

Read more

SelectMDx for Prostate Cancer Guides Patient Selection for mpMRI

Read more

argenx announces size of initial public offering in the United States increased to 5 million ADSs

Read more

SLims by Genohm integrated with Pathomation’s PMA.core

Read more

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Read more

Cochlear acquires exclusive licence to Artificial Intelligence assistant

Read more

argenx to Present at JMP Securities Life Sciences Conference

Read more

argenx receives second preclinical milestone payment in collaboration with LEO Pharma

Read more

Mithra Completes Recruitment for Additional Estelle® Safety Study

Read more

Estelle® Phase IIB results on well-being and body weight published in leading peer-reviewed journal

Read more

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein

Read more

argenx to Present at Wedbush PacGrow Healthcare Conference

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Read more

New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston

Read more

argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results

Read more

argenx announces publication of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116

Read more

Bone Therapeutics announces H1 results for 2017

Read more

TiGenix strengthens US operations with senior appointments

Read more

ABL acquisition extends Ardena’s early-phase offering

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

Read more

Pharmacokinetics in Drug Development - 2017

Read more

TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting

Read more

Bridging Preclinical and Clinical Development

Read more

ThromboGenics Business Update - Q3 2017

Read more

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

Read more

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017

Read more

Galapagos moving forward in CF programs at NACFC 2017

Read more

OCTIMET Oncology NV awarded €1.12 million grant from VLAIO

Read more

ThromboGenics Strengthens Leadership Team

Read more

argenx to Present at Upcoming Investor Conferences

Read more

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

Read more

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

Read more

Promethera Biosciences Provides Update on Executive Management Team

Read more

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Read more

Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany

Read more

Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests

Read more

Fast Track Diagnostics and UgenTec announce new interpretation software for all FTD real-time PCR multiplex kits

Read more

Mithra Finalizes Estelle® Contract with Brazilian Women’s Health Leader Libbs

Read more

Press Release - Life Sciences & Biotechnology

Read more

argenx announces launch of proposed public offering in the United States

Read more

argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering

Read more

Bone Therapeutics Launches Equity Placement

Read more

argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million

Read more

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Read more

Galapagos - Update on progress in cystic fibrosis programs

Read more

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies

Read more

Bone Therapeutics provides business outlook and announces its financial calendar for 2018

Read more

Mithra announces very promising hemostasis results for Estelle®

Read more

Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more

Argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018

Read more

European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects

Read more

Biocartis announces 2017 results and 2018 outlook

Read more

CMAST supports Rejuvenate Biomed in their search for ways to impact the ageing process

Read more

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Read more

Argenx to Present at Cowen & Company 38th Annual Health Care Conference

Read more

Mithra presents positive hemostasis results at ISGE conference

Read more

Argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies

Read more

Argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

Read more

ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

Read more

Promethera Biosciences Announces Updates to its Board of Directors

Read more

Mithra signs principle agreement for commercialization of Estelle® in canada

Read more

Bone Therapeutics Reports Full Year 2017 Results

Read more

Biocartis Q1 2018 business update

Read more

ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

Read more

Bone Therapeutics Business Update for First Quarter 2018

Read more

ThromboGenics Business Update - Q1 2018

Read more

Biocartis: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference

Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Read more

Biocartis Group NV: Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Read more

Mithra signs binding heads of terms for commercialization of Estelle® in South Korea with women's health specialist Hyundai Pharm

Read more

argenx selected for BEL 20 Index

Read more

argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018

Read more

Bone Therapeutics announces results of Annual General Meeting

Read more

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

Read more

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Read more

Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

Read more

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Read more

New Study Shows MDxHealth's SelectMDx Test is Cost-Effective for Biopsy Selection

Read more

RegMed

Read more

Specialized blood vessels enhance tumor-fighting immunotherapy

Read more

REVERSED BREXIT: £250 MILLION FOR BART DE STROOPER'S DEMENTIA RESEARCH

Read more

Biogazelle offers unique mRNA sequencing on plasma

Read more

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

Nieuws van de dag - 27/04/2017

Read more

Celyad initiates second dose escalation in THINK trial in first US patient

Read more

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Read more

VIB: A new unexpected key player in melanoma development identified

Read more

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Read more

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

Read more

Biocartis Group NV: Biocartis announces its new CEO

Read more

TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York

Read more

FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®

Read more

VIB: Researchers identify nutrient metabolism that drives breast tumor metastasis

Read more

Mithra to Initiate PK Study for Estelle®

Read more

ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men

Read more

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Read more

Biocartis Group NV: Biocartis launches CE-marked IVD NRAS test for colorectal cancer

Read more

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Read more

Nieuws van de dag- 30/05/2017

Read more

Smart Implant & (Bio-)medical Imaging Platform Meeting

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

Read more

TiGenix announces final equity payment for cardiac platform acquisition

Read more

Services

Read more

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017

Read more

Symposium on Liquid Biopsies & Cancer

Read more

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

Read more

MDxHealth Presents Three SelectMDx Studies at 5th Global Congress on Prostate Cancer

Read more

iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development

Read more

TiGenix opens US headquarters in Cambridge, MA

Read more

Lack of Knowledge on Clinical Advances Achieved by New Generation of Biomarker Tests for Prostate Cancer

Read more

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

Read more

SelectMDx to be Distributed Across Middle East by IPS Genomix

Read more

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

Read more

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Read more

QBD Webinar on validation of mobile apps

Read more

Celyad announces new agreements with Celdara medical and Dartmouth College

Read more

Immunity for Health 2017

Read more

Mithra: Recruitment Completed in Estelle® Population PK Substudy

Read more

ConfirmMDx Study Provides Further Validation of Epigenetic Risk Profile

Read more

Mithra Announces First Subject Completes Estelle® Phase III Study

Read more

Celyad Reports First Half 2017 Financial Results and Operational Progress

Read more

ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

Read more

Biocartis announces H1 2017 results

Read more

ThromboGenics Business Update - H1 2017

Read more

SelectMDx Outperforms PCA3 Stratifying Men for mpMRI

Read more

Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

Read more

Bone Therapeutics reports strong interim results from ALLOB® Phase IIA spinal fusion study

Read more

Ardena launches following Pharmavize and Crystallics merger

Read more

Bone Therapeutics announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

Read more

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Read more

Life sciences meets micro-nanoelectronics: zooming in on MEDICAL DEVICES

Read more

Mithra Signs Commercial Agreement With Brazilian Leader in Women’s Health Libbs for Estelle® in Brazil

Read more

Ablynx files registration statement for a proposed global offering

Read more

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Read more

Scientists pinpoint surprising origin of melanoma

Read more

Mithra Announces Completion of Recruitment in Donesta® Phase II Study

Read more

Ablynx announces launch of proposed global offering

Read more

Newly described process in Parkinson’s protein as a potential new therapy route

Read more

Ablynx - Notice in Relation to the Convertible bonds due May 2020

Read more

Ablynx announces full exercise of underwriters' option to purchase additional shares and end of stabilization period

Read more

Bio Base NWE project wins RegioStars Award 2017

Read more

Ablynx closes $200 Million Initial Public Offering in the United States

Read more

Ablynx closes on underwriters' option to purchase $30 million of additional shares in the U.S. initial public offering

Read more

MDxHealth Nine Month Trading Update

Read more

Press Release - Life Sciences & Biotechnology

Read more

New start-up Aelin Therapeutics secures 27M Euros to pioneer the development of a novel drug modality

Read more

New at Poulpharm: Animal facility for studies demanding high-containment levels

Read more

Ablynx to present at the 36th annual J.P. Morgen Healthcare conference

Read more

Imec’s SWEET study Collects World’s Largest Dataset on Stress Detection

Read more

VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

Read more

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

Read more

UgenTec and MDxHealth sign partnership agreement for software to support interpretation of molecular test results

Read more

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Read more

New collaboration between VIB and Plant Impact plc: advancing crop enhancement small molecule discovery

Read more

Sanofi to acquire Ablynx for €3.9 Billion

Read more

MDxHealth financial results

Read more

MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines

Read more

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Read more

Mithra Announces Completion of Estelle® Cycles Required in Phase III Contraception Studies

Read more

Novosanis’ medical device Colli-Pee® prefilled with urine preservative now CE-certified

Read more

MDxHealth Provides First Quarter 2018 Business Update

Read more

Mithra Announces Last Subject Visit in Estelle® Phase III Study in EU/Russia and Completion of Endometrial Substudy

Read more

Ardena acquires Syntagon and strengthens API offering

Read more

Do you have to become officially a BIOBANK under the new Belgian law?

Read more

Call for candidacies for the Board of Directors of flanders.bio

Read more

CoBioRes receives a € 1.7M grant from VLAIO to support its tetrapeptide prodrug research for treatment of Triple Negative Breast Cancer

Read more

MDxHealth (R): Presentation of New Data on MDxHealth's Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting

Read more

MDxHealth launch agreement with Philips for prognostic prostate cancer biomarker

Read more

CMAST attends the 2nd General Assembly of RESCEU; a European project focusing on the battle against RSV (June 21st-22nd, Oxford - UK)

Read more

Biocartis present at investor event VFB Happening this Saturday 25 March, Antwerp, BE

Read more

Galapagos: Publication of the annual report

Read more

Belgian PCR interpretation software company UgenTec partners with multiplex molecular diagnostics innovator PathoFinder

Read more

Biocartis Group NV: Biocartis establishes US subsidiary and appoints US General Manager

Read more

Innovation Platforms & Projects

Read more

TiGenix reports 2016 full year results

Read more

Galapagos increases share capital through warrant exercises

Read more

PersoMed Towers

Read more

Symposium on Sepsis

Read more

Galapagos raises $338 million gross proceeds in a U.S. public offering

Read more

Galapagos announces launch of proposed public offering

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

Read more

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

Read more

Galapagos announces capital increase

Read more

Metastatic breast cancers: Characterising the profile of metastases for improved treatment

Read more

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Read more

ONTOFORCE and Ghent University launch a new innovative ‘text mining’ project

Read more

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Read more

MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Read more

MDxHealth Trading Update: January to April 2017

Read more

Pauwels Consulting neemt Vandycke & Partners en Mediconsult over

Read more

Genohm at Pathology Informatics Summit 2017 in Pittsburgh

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas

Read more

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

Read more

ThromboGenics Business Update - Q1 2017

Read more

Biocartis Group NV: Results of the annual shareholders' meeting held on 12 May 2017

Read more

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Read more

Galapagos to hold Annual R&D Update 2017 on 20 June

Read more

Biocartis Group NV: Study demonstrating high performance of Idylla(TM) liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Read more

Galapagos creates new warrant plan

Read more

argenx announces full exercise of underwriters' option to purchase additional ADSs

Read more

Innovative software Moon autonomously diagnoses rare diseases within minutes

Read more

argenx announces closing of NASDAQ IPO

Read more

Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors

Read more

Celyad obtains additional US patent for cancer treatment

Read more

Cell Death and Immunity in Disease: from molecules to translational medicine

Read more

Biocartis wins prestigious Galenus Prize with its Idylla(TM) NRAS-BRAF Mutation Test for colorectal cancer

Read more

TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

ThromboGenics to Present the Industry Pipeline of DME Treatments

Read more

Mithra Receives Orphan Drug Designation from EMA for E4 in Neonatal Encephalopathy

Read more

Biocartis launches CE-marked IVD test for lung cancer

Read more

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Read more

Daily Newsflash- 14/06/17

Read more

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

Read more

MDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test

Read more

Galapagos' R&D Update 2017: rapidly advancing our product candidates

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

Mithra Launches a Capital Increase by Means of a Private Placement via an Accelerated Bookbuild Offering

Read more

Celyad publishes additional pre-clinical data in support of THINK trial

Read more

Mithra Successfully Raises €26.1 Million

Read more

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

Expertise

Read more

Ablynx achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA

Read more

flanders.bio strenghtens its team with the appointment of 3 Programme Managers

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Bone Therapeutics Strengthens Board of Directors

Read more

UgenTec moves into PCR middleware, partners with Haman Laborautomation

Read more

Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

Read more

Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis

Read more

Biocartis Group NV: Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

Read more

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer’s disease

Read more

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test

Read more

TiGenix: Transparency Information

Read more

ConfirmMDx Featured in OncologyLive Magazine

Read more

MDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion

Read more

MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group

Read more

iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Read more

UgenTec receives €50.000 grant by European Union

Read more

Bone Therapeutics Notice of Half Year 2017 Results

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

Press Release - Life Sciences & Biotechnology

Read more

OLVZ Aalst User Experience Day

Read more

Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

Read more

MDxHealth Announces First Half 2017 Financial Results

Read more

Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO

Read more

Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017

Read more

TiGenix obtains commercial production license for expanded manufacturing facility

Read more

Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

Read more

MDxHealth Prepares for Growth with Executive Team Expansion

Read more

Biocartis Group NV: Results of the extraordinary shareholders' meeting held on 11 September 2017

Read more

flanders.bio - CMAST Partner Day: Realizing Life Science Innovation with Impact

Read more

ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

Read more

Mithra announces 2017 half year results

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Galapagos werft aan

Read more

Promethera Biosciences to Present at Several International Partnering and Scientific Conferences this Fall

Read more

ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

Read more

TiGenix to participate and present at key investor and business development meetings

Read more

ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

Read more

Dutch Life Sciences conference

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017

Read more

Ablynx prices $200 million Initial Public Offering in the United States

Read more

MyCartis appoints Philippe Stas as CEO

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

TiGenix strengthens European IP protection around lead development program Cx601

Read more

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

Read more

TiGenix announces partial conversion of bonds

Read more

iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Biocartis Group NV: Idylla(TM) Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference

Read more

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Read more

Galapagos increases share capital through warrant exercises

Read more

JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix

Read more

Biocartis successfully raises EUR 80 million in an equity placement

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate

Read more

Press Release - Life Sciences & Biotechnology

Read more

Galapagos to enter NASDAQ Biotech Index

Read more

Galapagos NV - Transparency notification

Read more

reMYND enters into license agreement with Novo Nordisk

Read more

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

Read more

Bone Therapeutics Provides Update on Equity Placement

Read more

Galapagos Transparency notification

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

MDxHealth Announces Lowering of 2017 Guidance

Read more

TiGenix Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Read more

Takeda announces its intention to acquire TiGenix

Read more

Galapagos - Positive topline results with GLPG1972 in osteoarthritis patients

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

Read more

Biocartis - Disclosure of a transparency notification

Read more

TiGenix - Transparency Information

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

TiGenix - Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease

Read more

new England biolabs® and Bluebee partner to deliver an end-to-end data analysis solution for Nebnext direct® target enrichment

Read more

Disclosure of a transparency notification

Read more

MDxHealth contract SelectMDx with Roman Hospital

Read more

Biocartis Establishes R&D Center in the US

Read more

Bone Therapeutics announces private placement of convertible bonds

Read more

Networking

Read more

Galapagos publication of the annual report and invitation to the annual shareholders' meeting

Read more

Press Release - Life Sciences & Biotechnology - 30/03/2018

Read more

TiGenix Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

Biocartis Group NV: Biocartis announces publication of its 2017 annual report

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data

Read more

Hamilton Robotics first company to join the UgenTec’s new Molecular Automation Network

Read more

Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model

Read more

Bone Therapeutics Notice of Full Year 2017 Results

Read more

Galapagos creates new warrant plan

Read more

MDxHealth (R): SelectMDx Included in Dutch DRG Reimbursement System

Read more

Bone Therapeutics Strengthens Board with the Appointment of Claudia D’Augusta as Non-Executive Director

Read more

Ablynx completes patient recruitment in the Phase IIb Respire Study of its inhaled anti-RSV Nanobody ALX-0171

Read more

Agilent Technologies to Enhance Lab Informatics with Acquisition of Genohm

Read more

Bone Therapeutics Information on the total number of voting rights and shares

Read more

Bone Therapeutics: preliminary documents for the Annual Ordinary and the Extraordinary General Shareholder Meeting

Read more

Biocartis: Results of the annual shareholders' meeting held on 11 May 2018

Read more

Promethera Biosciences Establishes Branch Office in Tokyo

Read more

GST raises EUR 5 million to develop veterinary stem cell products

Read more

Press Release - Life Sciences & Biotechnology - 23/05/2018

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

Galapagos Transparency notification

Read more

Galapagos increases share capital through warrant exercises

Read more